tiprankstipranks
MaxCyte Inc (MXCT)
NASDAQ:MXCT

MaxCyte (MXCT) Income Statement

52 Followers

MaxCyte Income Statement

Last quarter (Q1 2024), MaxCyte's total revenue was $11.34M, an increase of 32.25% from the same quarter last year. In Q1, MaxCyte's net income was $-9.53M. See MaxCyte’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 44.05M$ 41.29M$ 44.26M$ 33.89M$ 26.17M$ 21.62M
Cost of Revenue
$ 5.15M$ 4.74M$ 5.10M$ -3.65M$ 2.77M$ 2.50M
Gross Profit
$ 38.91M$ 36.55M$ 39.16M$ 30.25M$ 23.40M$ 19.12M
Operating Expense
$ 86.31M$ 84.84M$ 66.52M$ -48.44M$ 34.46M$ 31.54M
Operating Income
$ -47.40M$ -48.30M$ -27.36M$ -18.19M$ -11.06M$ -12.42M
Net Non Operating Interest Income Expense
$ 10.83M$ 10.38M$ 3.92M$ 150.80K$ -759.70K$ -475.00K
Other Income Expense
$ 339.49K$ -6.51K$ 126.90K$ 1.04M--
Pretax Income
$ -36.57M$ -37.92M$ -23.57M$ -19.08M$ -11.82M$ -12.89M
Tax Provision
$ -8.75M$ -8.75M$ -2.58M$ -2.57M--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -36.57M$ -37.92M$ -23.57M$ -19.08M$ -11.82M$ -12.89M
Basic EPS
$ -0.35$ -0.37$ -0.23$ -0.21$ -0.17$ -0.23
Diluted EPS
$ -0.35$ -0.37$ -0.23$ -0.21$ -0.17$ -0.23
Basic Average Shares
$ 414.32M$ 103.27M$ 101.70M$ 90.62M$ 69.46M$ 56.40M
Diluted Average Shares
$ 414.32M$ 103.27M$ 101.70M$ 90.62M$ 69.46M$ 56.40M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 91.45M$ 89.59M$ 71.62M$ -52.08M$ 37.23M$ 34.04M
Net Income From Continuing And Discontinued Operation
$ -36.57M$ -37.92M$ -23.57M$ -19.08M$ -11.82M$ -12.89M
Normalized Income
$ -22.92M$ -46.67M--$ -11.82M$ -12.89M
Interest Expense
----$ 825.60K$ 681.10K
EBIT
$ -42.13M$ -37.92M$ -23.57M$ -19.09M$ -10.99M$ -12.21M
EBITDA
$ -41.21M$ -40.48M$ -23.54M$ -17.74M$ -9.94M$ -11.60M
Currency in USD

MaxCyte Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis